Epoxudine — Competitive Intelligence Brief

Epoxudine (EDOXUDINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: edoxudine. Area: Infectious Disease.

phase 2 edoxudine Thymidine kinase Infectious Disease Small molecule

Target snapshot

Epoxudine (EDOXUDINE). Edoxudine is thought to work by inhibiting viral replication, although the exact mechanism is unclear.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epoxudine TARGET	EDOXUDINE		phase 2	edoxudine	Thymidine kinase
Retrovir	ZIDOVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Thymidine kinase, cytosolic	1987-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Bravavir	SORIVUDINE		marketed	sorivudine	Thymidine kinase, mitochondrial, Deoxynucleoside kinase, Thymidine kinase
Fluoro-L-thymidine-(18F)	Fluoro-L-thymidine-(18F)	Assistance Publique - Hôpitaux de Paris	phase 3	PET imaging agent / radiopharmaceutical	Thymidine kinase 1 (TK1)
Trifluridine-tipiracil	Trifluridine-tipiracil	The Methodist Hospital Research Institute	phase 3	Nucleoside analog	Thymidine kinase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (edoxudine class)

1. · 1 drug in this class